EF Hutton analyst Elemer Piros initiated coverage of Compass Pathways with a Buy rating and $38 price target. Compass is expected to become the first to treat refractory depression with a psychedelic drug, Piros tells investors in a research note. The analyst says the company is in a leading position to bring psilocybin to the treatment-resistant depression market worldwide, by conducting clinical trials acceptable to regulatory agencies.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CMPS:
- Rising High: Exclusive talk with market research firm Brightfield Group
- Compass Pathways price target lowered to $33 from $55 at Oppenheimer
- Here’s What You Missed in Cannabis This Week
- Compass Pathways presents new COMP360 psilocybin therapy data
- COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP
